HighMark Wealth Management LLC Grows Position in AnaptysBio, Inc. $ANAB

HighMark Wealth Management LLC increased its holdings in AnaptysBio, Inc. (NASDAQ:ANAB) by 58.2% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 145,550 shares of the biotechnology company’s stock after purchasing an additional 53,550 shares during the period. AnaptysBio comprises about 1.6% of HighMark Wealth Management LLC’s portfolio, making the stock its 11th largest holding. HighMark Wealth Management LLC’s holdings in AnaptysBio were worth $3,231,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of ANAB. First Light Asset Management LLC boosted its holdings in shares of AnaptysBio by 433.3% during the 1st quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock valued at $86,139,000 after acquiring an additional 3,764,720 shares during the last quarter. Caption Management LLC lifted its position in AnaptysBio by 106.3% during the first quarter. Caption Management LLC now owns 23,376 shares of the biotechnology company’s stock valued at $435,000 after purchasing an additional 394,634 shares during the period. Woodline Partners LP boosted its holdings in AnaptysBio by 63.1% in the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock worth $14,705,000 after purchasing an additional 305,950 shares during the last quarter. 683 Capital Management LLC bought a new stake in AnaptysBio in the 1st quarter worth approximately $3,637,000. Finally, Palo Alto Investors LP raised its stake in AnaptysBio by 20.9% during the 1st quarter. Palo Alto Investors LP now owns 1,020,713 shares of the biotechnology company’s stock valued at $18,975,000 after buying an additional 176,742 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ANAB shares. Wedbush restated an “outperform” rating and issued a $45.00 price target on shares of AnaptysBio in a research note on Tuesday. JPMorgan Chase & Co. increased their target price on AnaptysBio from $42.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. HC Wainwright boosted their price target on AnaptysBio from $38.00 to $59.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, UBS Group reaffirmed a “neutral” rating and set a $20.00 price target (up previously from $18.00) on shares of AnaptysBio in a research report on Tuesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, AnaptysBio currently has a consensus rating of “Moderate Buy” and an average price target of $48.75.

AnaptysBio Stock Down 2.0%

Shares of ANAB opened at $31.34 on Friday. The business has a 50-day simple moving average of $22.34 and a two-hundred day simple moving average of $21.74. AnaptysBio, Inc. has a 52 week low of $12.21 and a 52 week high of $36.54. The stock has a market cap of $877.52 million, a price-to-earnings ratio of -7.00 and a beta of -0.18.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.16. The firm had revenue of $22.26 million for the quarter, compared to analysts’ expectations of $11.55 million. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%. On average, equities analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.